Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BrainChild-03: B7-H3 CAR T Cell Therapy for Pediatric CNS Tumors
NCT04185038Phase 1Recruiting
- Sponsor
- Seattle Children's
- Start
- Dec 2019
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCB-276 in diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG) and central nervous system tumor (5 arms), sponsored by Seattle Children's. Primary endpoints: Safety defined by adverse events at 7 months and Feasibility of CAR T cell production and administration at 28 days. Started Dec 2019; status: recruiting.
02
Drugs
BCB-276
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)central nervous system tumor
Beyond the preview
Go deeper on NCT04185038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185038.